Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
CytomX TherapeuticsCTMX | Open-market sale | 06/15 | 06/17 | 1,624 sh | $3.05 | $4,953.2 | −0.5% | |
CytomX TherapeuticsCTMX | Open-market sale10b5-1 plan | 03/17 | 03/19 | 118,969 sh | $6.42 | $763,780.98 | −9.9% | |
Yu-Waye ChuChief Medical Officer | CytomX TherapeuticsCTMX | Open-market sale | 03/17 | 03/19 | 21,279 sh | $6.42 | $136,611.18 | −10.1% |
CytomX TherapeuticsCTMX | Open-market sale | 03/17 | 03/19 | 19,323 sh | $6.42 | $124,053.66 | −6.1% | |
Marcia BelvinSVP, Chief Scientific Officer | CytomX TherapeuticsCTMX | Open-market sale | 03/17 | 03/19 | 31,492 sh | $6.42 | $202,178.64 | −9.5% |
CytomX TherapeuticsCTMX | Open-market sale10b5-1 plan | 25/11/06 | 25/11/10 | 101,793 sh | $4.54 | $462,140.22 | −9.3% | |
CytomX TherapeuticsCTMX | Open-market sale | 25/06/16 | 25/06/17 | 55,511 sh | $2.69 | $149,324.59 | −4.8% | |
CytomX TherapeuticsCTMX | Open-market sale | 25/06/13–25/06/16 | 25/06/17 | 12,255 sh2 trades | $2.72avg. | $33,392.61 | −5.1% | |
Marcia BelvinSVP, Chief Scientific Officer | CytomX TherapeuticsCTMX | Open-market sale | 25/06/16 | 25/06/17 | 13,884 sh | $2.69 | $37,347.96 | −4.9% |
Lloyd A. RowlandGeneral Counsel | CytomX TherapeuticsCTMX | Open-market sale | 25/03/18 | 25/03/20 | 10,203 sh | $0.60 | $6,121.8 | −7.8% |
CytomX TherapeuticsCTMX | Open-market sale | 25/03/18 | 25/03/20 | 37,656 sh | $0.60 | $22,593.6 | −3.6% | |
Yu-Waye ChuChief Medical Officer | CytomX TherapeuticsCTMX | Open-market sale | 25/03/18 | 25/03/20 | 4,025 sh | $0.60 | $2,415 | −2.9% |
CytomX TherapeuticsCTMX | Open-market sale | 25/03/18 | 25/03/20 | 8,551 sh | $0.60 | $5,130.6 | −4.1% | |
Marcia BelvinSVP, Chief Scientific Officer | CytomX TherapeuticsCTMX | Open-market sale | 25/03/18 | 25/03/20 | 19,512 sh | $0.60 | $11,707.2 | −7.3% |
Lloyd A. RowlandGeneral Counsel | CytomX TherapeuticsCTMX | Open-market sale | 24/08/20 | 24/08/22 | 4,181 sh | $1.23 | $5,142.63 | −3.1% |
CytomX TherapeuticsCTMX | Open-market sale | 24/08/20 | 24/08/22 | 13,898 sh | $1.23 | $17,094.54 | −2.1% | |
CytomX TherapeuticsCTMX | Open-market sale | 24/08/20 | 24/08/22 | 1,984 sh | $1.23 | $2,440.32 | −1.8% | |
Jeffrey B. LandauChief Business Officer | CytomX TherapeuticsCTMX | Open-market sale | 24/08/20 | 24/08/22 | 4,181 sh | $1.23 | $5,142.63 | −3.4% |
Marcia BelvinSVP, Chief Scientific Officer | CytomX TherapeuticsCTMX | Open-market sale | 24/08/20 | 24/08/22 | 4,181 sh | $1.23 | $5,142.63 | −2.3% |
Lloyd A. RowlandGeneral Counsel | CytomX TherapeuticsCTMX | Open-market sale | 24/03/19 | 24/03/21 | 5,268 sh | $2.09 | $11,010.12 | −4.3% |